STOCK TITAN

Inovio Pharmaceuticals Inc - INO STOCK NEWS

Welcome to our dedicated news page for Inovio Pharmaceuticals (Ticker: INO), a resource for investors and traders seeking the latest updates and insights on Inovio Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inovio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inovio Pharmaceuticals's position in the market.

Rhea-AI Summary
INOVIO's CEO, Dr. Jacqueline Shea, will participate in The Novel Therapeutics Forum hosted by Citizens JMP to discuss innovative technologies for treating and preventing diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.25%
Tags
conferences
-
Rhea-AI Summary
INOVIO Announces Positive Progress with Lead Program for Recurrent Respiratory Papillomatosis (RRP) and Financial Results for Q4 and Full Year 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
earnings
-
Rhea-AI Summary
Geneos Therapeutics announces the presentation of new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, at the 2024 AACR Annual Meeting. The data includes the use of GNOS-PV02 in combination with pembrolizumab for advanced hepatocellular carcinoma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
conferences clinical trial
Rhea-AI Summary
INOVIO to Release Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
conferences earnings
-
Rhea-AI Summary
INOVIO (NASDAQ:INO) announced that Dr. Jacqueline Shea, President and CEO, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The conference will include one-on-one meetings with registered investors and a webcast of the presentation. INOVIO is a biotechnology company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
conferences
-
Rhea-AI Summary
INOVIO (NASDAQ:INO) has announced an equity grant to a newly hired employee under its 2022 Inducement Plan. The grant includes restricted stock units (RSUs) covering 3,750 shares of common stock and an option to purchase 5,833 shares of common stock. The RSUs will vest over a three-year period, with one-third of the shares vesting on each of the first, second, and third anniversaries of the Grant Date. The stock option has an exercise price of $5.39, the closing price of INOVIO's common stock on the Grant Date. The vesting of the RSUs and stock option is subject to the employee's continued employment with INOVIO on the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
Rhea-AI Summary
INOVIO announces a 1-for-12 reverse stock split to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse stock split will reduce the number of issued and outstanding shares from approximately 280.1 million to approximately 23.3 million, with no change in the par value per share. Fractional shares will not be issued, and stockholders entitled to receive a fractional share will receive a cash payment. The reverse stock split will not reduce the number of authorized shares of the company's common stock, which will remain at 600,000,000 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.15%
Tags
stock split
-
Rhea-AI Summary
INOVIO to participate in a virtual fireside chat to discuss potential treatment of Recurrent Respiratory Papillomatosis (RRP) with key panel participants including Dr. Jacqueline Shea, Dr. Michael Sumner, and Dr. Simon Best. The event will be moderated by Hartaj Singh of Oppenheimer & Co. Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
conferences
-
Rhea-AI Summary
INOVIO (INO) and Coherus BioSciences (CHRS) to evaluate combination therapy in Phase 3 trial for patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
Rhea-AI Summary
INOVIO (INO) and Coherus BioSciences (CHRS) to evaluate combination therapy in Phase 3 trial for patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.62%
Tags
none
Inovio Pharmaceuticals Inc

Nasdaq:INO

INO Rankings

INO Stock Data

304.52M
22.99M
1.61%
18.5%
8.17%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
US
San Diego

About INO

inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.